No relief for Novo Nordisk: HC refuses interim stay on order letting Dr Reddy’s make, export weight-loss drug

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...
Healio

FDA approves berotralstat for children aged 2 to 12 years with hereditary angioedema

The FDA has approved berotralstat oral pellets for prophylactic use in patients aged 2 to than 12 years with hereditary ...

NIPER inks MoU with tibbi college

Patna: The National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, on Friday inked a memorandum of ...

Weight-loss drug Ozempic launched in India, priced at Rs 8,800 a month

Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four ...

FDA approves BioCryst's oral pellet version of swelling disorder drug for children

The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent ...
PharmExec

Brent Saunders: Eyeing New Horizons

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug

BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to children ages 2 to under 12.

FDA expands approval of BioCryst's rare disease drug for use in young children

Food ‌and Drug Administration ‌has expanded the use of ⁠BioCryst ‌Pharmaceuticals' drug to include ‍an oral pellet ...
TipRanks on MSN

BioCryst gains FDA approval for pediatric HAE drug

BioCryst ( ($BCRX) ) has provided an announcement. On December 12, 2025, BioCryst Pharmaceuticals announced the FDA approval of its new drug ...
Cosmetics Business

FDA unveils plans for new sunscreen ingredient use in US products

The US Food and Drug Administration (FDA) agency is proposing to add bemotrizinol as a permitted active ingredient for use in ...
The Manila Times

BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to

ORLADEYO is now the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and above. A capsule ...

FDA approves BioCryst's oral pellet formulation of rare disease drug for young children

The U.S. Food and Drug Administration has approved an oral pellet formulation of BioCryst Pharmaceuticals' drug to prevent hereditary angioedema attacks in children aged 2 to under 12, the company ...